Berberine (CAS 2086-83-1): AMPK Activator for Metabolic and Inflammation Research

Executive Summary: Berberine (CAS 2086-83-1) is a plant-derived isoquinoline alkaloid with a molecular weight of 336.36 and chemical formula C₂₀H₁₈NO₄ [product dossier]. It acts as a direct activator of AMP-activated protein kinase (AMPK), modulating glucose and lipid metabolism in cellular and animal models (Li et al., 2025). Berberine upregulates low-density lipoprotein receptor (LDLR) expression in hepatoma cell lines at concentrations up to 15 μg/mL. It exerts anti-inflammatory effects via NLRP3 inflammasome modulation, relevant to acute and chronic inflammation [internal review]. In vivo, oral dosing of 50–100 mg/kg/day reduces serum cholesterol and LDL in hyperlipidemic hamsters. The compound is insoluble in water and ethanol but dissolves ≥14.95 mg/mL in DMSO; optimal solution preparation requires heating or ultrasonic agitation.

Biological Rationale

Berberine is primarily isolated from Cortex Phellodendri Chinensis and related Berberis species. Its pharmacological profile includes modulation of metabolic homeostasis, anti-inflammatory effects, and antimicrobial actions. AMPK activation is central to its mechanism, influencing energy balance and metabolic signaling pathways. Berberine is widely used in research models of diabetes, obesity, and cardiovascular disease due to its ability to regulate glucose uptake, lipid metabolism, and inflammatory mediators (Li et al., 2025). The modulation of LDL receptor levels and NLRP3 inflammasome activity further supports its dual utility in metabolic and inflammation research [review]. This article extends prior work by integrating quantitative benchmarks from both cellular and animal models, clarifying dose-dependent effects.

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine exerts its primary effects via activation of AMP-activated protein kinase (AMPK), a cellular energy sensor. AMPK activation enhances glucose uptake, inhibits gluconeogenesis, and promotes fatty acid oxidation. In human hepatoma cell lines (HepG2, Bel-7402), berberine induces a dose-dependent upregulation of LDLR mRNA and protein, with maximal induction at 15 μg/mL [N1368 kit]. Inflammatory modulation is mediated by suppression of the NLRP3 inflammasome, a multiprotein complex linked to sterile inflammation and metabolic stress. Recent studies show that berberine can interfere with the NEK7-NLRP3 interaction, reducing inflammasome activation and downstream cytokine release (Li et al., 2025). This positions berberine as a dual-modality agent for metabolic and inflammation research.

Evidence & Benchmarks

• Berberine is insoluble in water and ethanol but dissolves at ≥14.95 mg/mL in DMSO at 37°C (product datasheet, apexbt.com).
• In HepG2 and Bel-7402 cells, berberine (up to 15 μg/mL) increases LDLR mRNA and protein in a dose-dependent fashion (see Table 1, product page).
• In hyperlipidemic golden hamsters, oral dosing at 50–100 mg/kg/day for 10 days reduces serum total cholesterol and LDL cholesterol (Li et al., 2025, DOI).
• Berberine activates AMPK and modulates metabolic signaling in diabetes and obesity models (Li et al., 2025, DOI).
• Berberine suppresses NLRP3 inflammasome activation in cell and animal models, reducing IL-1β/IL-18 secretion (mechanism figure, DOI).
• Stock solutions are optimally stored below -20°C; long-term storage in solution is not recommended (product datasheet, apexbt.com).

Applications, Limits & Misconceptions

Berberine is extensively used in metabolic disease models, including diabetes (Type 2), obesity, and atherosclerosis. Its capacity to upregulate LDLR and improve lipid profiles makes it a preferred tool in cardiovascular research [mechanistic review]. This article clarifies the translational range by detailing quantitative dosing data and highlighting anti-inflammatory mechanisms relevant to acute kidney injury and sterile inflammation.

Common Pitfalls or Misconceptions

• Berberine is not effective as a direct anti-viral agent; its antimicrobial effects are primarily antibacterial and antifungal (no evidence for broad-spectrum antiviral efficacy).
• It does not substitute for statins in clinical lipid lowering; effects are observed primarily in preclinical models.
• Berberine's in vivo efficacy is dose- and time-dependent; subtherapeutic dosing fails to yield significant metabolic changes.
• Oral bioavailability in mammals is low due to efflux and first-pass metabolism; in vitro and in vivo concentrations are not directly comparable.
• Long-term solution storage at room temperature or above -20°C degrades compound integrity.

Workflow Integration & Parameters

For laboratory use, berberine is supplied as a solid and should be stored at -20°C, sealed and protected from moisture and heat. It should be dissolved in DMSO (≥14.95 mg/mL), with warming at 37°C or ultrasonic agitation recommended for complete dissolution. Stock solutions should be aliquoted and used promptly; avoid repeated freeze-thaw cycles. In cellular experiments, effective concentrations range from 1–15 μg/mL, with maximal LDLR upregulation at 15 μg/mL in HepG2 cells. In animal models, oral dosing from 50–100 mg/kg/day is standard for metabolic endpoints. For acute inflammation and pyroptosis studies, dosing and timing should be referenced from peer-reviewed protocols (see Li et al., 2025). For ordering and detailed specifications, see Berberine (CAS 2086-83-1) at apexbt.com.

Conclusion & Outlook

Berberine (CAS 2086-83-1) is a validated research tool for metabolic and inflammation studies, with atomic evidence for AMPK activation, LDLR upregulation, and NLRP3 inflammasome modulation. Its solubility profile and handling requirements are well-defined, supporting reproducible research workflows. Ongoing studies are clarifying its translational relevance for cardiometabolic and inflammatory diseases. This article updates and extends previous mechanistic summaries [see prior review] by integrating product-specific benchmarks and clarifying dosing boundaries for reliable experimental outcomes.